Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial

Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hundertmark, Moritz J., Adler, Amanda, Antoniades, Charalambos, Coleman, Ruth, Griffin, Julian L., Holman, Rury R., Lamlum, Hanan, Lee, Jisoo, Massey, Daniel, Miller, Jack J.J.J., Milton, Joanne E., Monga, Shveta, Mózes, Ferenc E., Nazeer, Areesha, Raman, Betty, Rider, Oliver, Rodgers, Christopher T., Valkovič, Ladislav, Wicks, Eleanor, Mahmod, Masliza, Neubauer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212585/
https://www.ncbi.nlm.nih.gov/pubmed/37070436
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212585/
https://www.ncbi.nlm.nih.gov/pubmed/37070436
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062021

Ejemplares similares